TMCnet News
www.PicksThatMove.com: "Picks that move" Alerts, September 10, 2009: FOLD, HURN, HEV, EXTR, BPSG and DYAX.(M2 PressWIRE Via Acquire Media NewsEdge) Picksthatmove.com Alerts include Amicus Therapeutics (Nasdaq: FOLD); Huron Consulting Group (NASDAQ: HURN); Ener1, Inc. (Nasdaq: HEV); Extreme Networks, Inc. (NASDAQ: EXTR); Broadpoint Gleacher Securities Group, Inc. (NASDAQ: BPSG) and Dyax Corp. (NASDAQ: DYAX) -- September 10, 2009 Amicus Therapeutics (Nasdaq: FOLD) trading at $10.29 on a volume of 1,600 shares. In a press release out on September 10, 2009 Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 14, 2009 CRANBURY, N.J., Sept 10, 2009 -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company's president and chief executive officer, John F. Crowley, will be presenting at the upcoming Morgan Stanley Global Healthcare Unplugged Conference. Mr. Crowley's presentation is scheduled to begin on Monday, September 14 at 5:05 p.m. EDT. About Amicus Therapeutics Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. -- September 10, 2009 Huron Consulting Group (NASDAQ: HURN) trading at $18.90 on a volume of 201,905 shares In a press release on September 10, 2009 Huron Consulting Group Names Johnson and Yaeger to Vice President Positions CHICAGO, Sep 10, 2009 -- Huron Consulting Group (NASDAQ: HURN), a leading provider of business consulting services, today announced the appointment of two vice presidents who will lead practices in the Company's Health and Education Consulting segment. About Huron Consulting Group Huron Consulting Group helps clients in diverse industries improve performance, comply with complex regulations, resolve disputes, recover from distress, leverage technology, and stimulate growth. The Company teams with its clients to deliver sustainable and measurable results. Huron provides services to a wide variety of both financially sound and distressed organizations, including leading academic institutions, healthcare organizations, Fortune 500 companies, medium-sized businesses, and the law firms that represent these various organizations. Learn more at www.huronconsultinggroup.com. -- September 10, 2009 Ener1, Inc. (Nasdaq: HEV) trading at $6.89 on a volume of 285,339 shares. In a press release out on September 10, 2009 Lithium-Ion Battery Maker Names New President EXPANDED MANAGEMENT TEAM ADDS NEW STRENGTH IN PRODUCT INDIANAPOLIS, Sept 10, 2009 -- Ener1, Inc. (Nasdaq: HEV) Advanced lithium-ion battery maker EnerDel, Inc. today named Richard L. Stanley as company President. Stanley is a proven leader with 30 years' global manufacturing and management experience and a distinguished record of creating new business lines. The move is one of three new executive appointments designed to position EnerDel for continued success in the next phases of its commercial evolution. The announcements come as automakers worldwide expand their commitment to hybrid and electric drive technologies and new market opportunities emerge in utility grid energy storage. About Ener1, Inc. Ener1 develops and manufactures compact, high performance lithium-ion batteries to power the next generation of hybrid, plug-in hybrid and pure electric vehicles. The publicly traded company (Nasdaq: HEV) is led by an experienced team of engineers and energy system experts at its EnerDel subsidiary located in Indiana. In addition to the automobile market, applications for Ener1 lithium-ion battery technology include the military, grid storage and other growing markets. Ener1 also develops commercial fuel cell products through its EnerFuel subsidiary and nanotechnology-based materials and manufacturing processes for batteries and other applications through its NanoEner subsidiary. -- September 10, 2009 Extreme Networks, Inc. (NASDAQ: EXTR) last at $2.64 on a volume of 88,890 shares In a press release out on September 10, 2009 eTelemetry Joins Extreme Networks Go Purple Partner Program Providing User Identity and Location Tools eTelemetry's Locate Provides Endpoint Visibility Without Having to Deploy NAC or Desktop Agents SANTA CLARA, CA, Sep 10, 2009 -- Extreme Networks, Inc. (NASDAQ: EXTR) and eTelemetry, a leader in extracting real-time business information from network activity, today announced that eTelemetry has joined Extreme Networks(R) Go Purple(TM) Partner Program, where the companies are teaming to provide best-of-breed and proven interoperable network solutions. Extreme Networks, Inc. Extreme Networks provides converged Ethernet networks that support data, voice and video for enterprises and service providers. The company's network solutions feature high performance and high availability switching that deliver insight and control enabling customers to solve their real-world business communications challenges. Operating in more than 50 countries, Extreme Networks provides wired and wireless secure LANs, data center infrastructure and Service Provider Ethernet transport solutions that are complemented by global, 24x7 service and support. For more information, visit http://www.extremenetworks.com -- September 10, 2009 Broadpoint Gleacher Securities Group, Inc. (NASDAQ: BPSG) trading at $8.56 on a volume of 381,800 shares. In a press release out on September 10, 2009 Broadpoint.Gleacher Expands High Yield, Preferred, and Convertible Efforts NEW YORK, Sep 10, 2009 -- Broadpoint Capital, Inc., a broker-dealer subsidiary of Broadpoint Gleacher Securities Group, Inc. (NASDAQ: BPSG), today announced the hiring of five senior professionals in its Debt Capital Markets division: Mark Colm, Quentin Murray, Michael Voelker, Ryan Goldman, and Kiera Perez-Konis. About Broadpoint.Gleacher Broadpoint Gleacher Securities Group, Inc. (NASDAQ: BPSG) is an independent investment bank that provides corporations and institutional investors with strategic, research-based investment opportunities, capital raising, and financial advisory services, including merger and acquisition, restructuring, recapitalization and strategic alternative analysis services. The Company offers a diverse range of products through the Debt Capital Markets, Investment Banking and Broadpoint DESCAP divisions of Broadpoint Capital, Inc., its new Investment Banking financial advisory subsidiary, Gleacher Partners LLC, its Equity Capital Markets subsidiary, Broadpoint AmTech and FA Technology Ventures Inc., its venture capital subsidiary. For more information, please visit www.bpsg.com. -- September 10, 2009 Dyax Corp. (NASDAQ:DYAX) trading at $3.97 on a volume of 434,098 shares In a press release out on September 10, 2009 Reliability and Validity of Dyax's Novel Patient Reported Outcome Measures (PROs) Affirmed in Published Study CAMBRIDGE, Mass., Sep 10, 2009 -- Dyax Corp. (NASDAQ:DYAX) today announced a study published evaluating the Company's novel Patient Reported Outcome Measures (PROs) used to assess hereditary angioedema (HAE) attacks affirmed the PROs as valuable instruments in capturing HAE symptom severity and impact of treatment. The study, "Psychometric Validation of Two Patient-Reported Outcome Measures to Assess Symptom Severity and Changes in Symptoms in Hereditary Angioedema," examined the PROs used in Dyax's HAE clinical development program and was published in the September issue of the journal Quality of Life Research. About Dyax Dyax is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development. Dyax's lead product candidate is DX-88 (ecallantide), a recombinant small protein that is currently being evaluated for its therapeutic potential in two separate indications. On June 1, 2009, Dyax submitted a response to the FDA's Complete Response letter regarding the review of Dyax's Biologics License Application (BLA) of DX-88 for the treatment of hereditary angioedema (HAE). The FDA accepted the submission and assigned Dyax's BLA a new Prescription Drug User Fee Act (PDUFA) action date of December 1, 2009. DX-88 has orphan drug designation in the U.S. and E.U., as well as Fast Track designation in the U.S., for this indication. Additionally, DX-88 is being evaluated in two Phase 2 trials for the reduction of blood loss during on-pump cardiothoracic surgery (CTS), which are being conducted by Dyax's partner, Cubist Pharmaceuticals. Dyax licensed to Cubist the intravenous formulation of DX-88 for surgical indications in North America and Europe. DX-88 and other compounds in Dyax's pipeline were identified using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. Dyax is headquartered in Cambridge, Massachusetts. For online information about Dyax Corp., please visit www.dyax.com. About PicksThatMove.com www.picksthatmove.com team of excellence strives to find undervalued, good momentum stock plays. We provide financial and investor relations services for small to mid-cap stocks with weekly and special newsletters to keep you informed of the latest movers. Unlike other sites, we explore, research, and understand all aspects of a company. We only recommend companies we feel has the potential for future higher valuations. Our seasoned research team is always looking for the next Xtreme Pick to send to you. www.picksthatmove.com is a leading stock website that provides free daily alerts on stocks that are moving up. www.picksthatmove.com also tracks small cap stocks that are on the brink of exploding. We also feature companies on our website with research report, analysis, and newsletters. To feature a company on our web site please contact us at [email protected] www.picksthatmove.com is an independent electronic publication that provides information on selected publicly traded companies. www.picksthatmove.com is not a registered investment advisor or broker-dealer. www.picksthatmove.com affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above. ((Comments on this story may be sent to [email protected])) (c) 2009 M2 COMMUNICATIONS |